DocMorris AG/Fr. DOCM
1D1W1MYTD1Y5YMAX
Capital at risk
About DocMorris AG
DocMorris AG is a company operating in the pharmaceutical and healthcare sector, specializing in the distribution of medications and health-related products primarily through digital channels. The company is headquartered in Switzerland and focuses on providing an online platform for customers to purchase prescription and over-the-counter medicines, as well as other health products. DocMorris AG leverages digital technology to offer convenient access to healthcare products, catering to a broad European market. The company's strategic use of e-commerce in the pharmacy sector positions it uniquely to meet the growing demand for online health services.
- Ticker
- Fr. DOCM
- Sector
- Consumer Essentials
- Primary listing
- XSWX
- Employees
- 1,337
- Headquarters
- Frauenfeld, Switzerland
- Website
- corporate.docmorris.com/en
DocMorris AG Metrics
BasicAdvanced
CHF 545M
-
-CHF 2.61
1.86
-
Price and volume
Market cap
CHF 545M
Beta
1.86
52-week high
CHF 11.25
52-week low
CHF 3.92
Average daily volume
330K
Financial strength
Current ratio
1.875
Quick ratio
1.529
Long term debt to equity
73.048
Total debt to equity
74.234
Interest coverage (TTM)
-4.92%
Profitability
EBITDA (TTM)
-75.615
Gross margin (TTM)
22.10%
Net profit margin (TTM)
-10.65%
Operating margin (TTM)
-7.25%
Effective tax rate (TTM)
-11.93%
Revenue per employee (TTM)
CHF 880,000
Management effectiveness
Return on assets (TTM)
-6.37%
Return on equity (TTM)
-30.05%
Valuation
Price to revenue (TTM)
0.435
Price to book
1.46
Price to tangible book (TTM)
-4.53
Price to free cash flow (TTM)
-6.358
Free cash flow yield (TTM)
-15.73%
Free cash flow per share (TTM)
-1.677
Growth
Revenue change (TTM)
11.29%
Earnings per share change (TTM)
-55.78%
3-year revenue growth (CAGR)
9.55%
10-year revenue growth (CAGR)
3.22%
3-year earnings per share growth (CAGR)
-19.24%
10-year earnings per share growth (CAGR)
5.97%
Bulls say / Bears say
DocMorris reported CHF 1.19 billion in external revenue for 2025—an 11.1% local currency increase—with Rx revenue up 33.2% and digital services more than doubling, driven by TeleClinic’s 2 million treatments and one-third of app users adopting its AI Assistant within three months (Reuters)
A strategic partnership with Google to develop a true AI-driven digital health companion accelerates DocMorris’s “AI-First” platform strategy and broadens its digital service offerings (Reuters)
Gematik extended approval of DocMorris’s CardLink digital prescription service until January 2027, ensuring regulatory continuity for its core telemedicine offering (Reuters)
Baader Helvea cut DocMorris to “reduce” from “add” citing an anticipated 125% share dilution from its planned capital increase, highlighting significant shareholder dilution risk (Reuters)
The company’s guidance forecasts a negative adjusted EBITDA of CHF 35–55 million for 2025, underscoring continued unprofitability through the year (Reuters)
Shares fell about 4% in premarket trading after H1 2025 sales missed consensus and growth of 10.2% lagged competitor Redcare’s 27.3%, pointing to competitive pressures in key markets (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
Upcoming events
No upcoming events
Funds containing DocMorris AG
AllUSDGBP
Fund name | Fund size | Fr. DOCM weighting |
|---|---|---|
iShares Digitalisation$DGTL | $793M | 0.02% |
iShares Digitalisation£DGIT | £587M | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.